Top Page
PharmAla Biotech Holdings, Inc.
(MDMA)
PharmAla Biotech Holdings, Inc. (MDMA) vs. iShares MSCI Canada ETF (EWC)
PharmAla Biotech Holdings, Inc. Business Overview & Revenue Model
PharmAla Biotech Holdings, Inc. Financial Statement Overview
| Breakdown | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 1.04M | 532.00K | 78.07K | 0.00 |
| Gross Profit | 887.44K | 454.10K | 75.78K | -303.00 |
| EBITDA | -573.36K | -710.18K | -973.45K | -2.51M |
| Net Income | -823.60K | -779.81K | -985.58K | -2.51M |
Balance Sheet | ||||
| Total Assets | 2.90M | 2.41M | 2.33M | 2.79M |
| Cash, Cash Equivalents and Short-Term Investments | 419.38K | 195.04K | 852.14K | 2.47M |
| Total Debt | 0.00 | 253.54K | 0.00 | 0.00 |
| Total Liabilities | 916.88K | 1.03M | 423.78K | 138.48K |
| Stockholders Equity | 1.98M | 1.38M | 1.91M | 2.66M |
Cash Flow | ||||
| Free Cash Flow | -547.78K | -846.39K | -1.62M | -435.76K |
| Operating Cash Flow | -321.36K | -339.66K | -625.37K | -173.57K |
| Investing Cash Flow | -226.42K | -506.74K | -994.87K | 629.22K |
| Financing Cash Flow | 772.12K | 189.29K | 0.00 | 2.02M |
PharmAla Biotech Holdings, Inc. Technical Analysis
PharmAla Biotech Holdings, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $7.37B | -0.04 | -63.81% | 2.59% | 16.40% | <0.01% | |
51 Neutral | C$10.57M | ― | -86.89% | ― | -69.15% | -184.72% | |
| ― | C$209.20K | ― | ― | ― | ― | ||
| ― | $562.01K | ― | ― | ― | ― | ||
33 Underperform | C$1.03M | ― | -258.31% | ― | ― | -36.54% | |
22 Underperform | C$9.27M | ― | 45.74% | ― | ― | ― | |
| ― | C$858.60K | ― | ― | ― | ― |
PharmAla Biotech Holdings, Inc. Corporate Events
PharmAla Biotech Holdings Inc. reported its Q2 financial results, highlighting significant growth in MDMA product sales and operational advancements. The company achieved a 95% year-over-year revenue increase, driven by a 73% rise in MDMA sales. Despite global supply chain challenges, PharmAla successfully resumed shipments in Canada and began fulfilling U.S. clinical trial sales, establishing a repeatable delivery process. The company’s strategic focus on its Prescriber’s Portal and new distribution partnerships is expected to drive recurring revenue and capitalize on increased demand.
Spark’s Take on TSE:MDMA Stock
According to Spark, TipRanks’ AI Analyst, TSE:MDMA is a Neutral.
PharmAla Biotech Holdings, Inc. shows potential due to strong revenue growth and strategic corporate events. However, profitability issues and bearish technical indicators weigh on the stock’s attractiveness. The company’s expansion into new markets and partnerships are positive, but effective cost and cash flow management remain crucial for future success.
To see Spark’s full report on TSE:MDMA stock, click here.
PharmAla Biotech Holdings Inc. has successfully completed an international shipment of its LaNeo™ MDMA to the University of Washington for clinical research, highlighting the company’s role in supporting important human research studies in the United States. Despite the successful delivery, the company acknowledges the ongoing risk posed by US-Canada cross-border trade uncertainties and advocates for tariff exemptions on investigational drug products for US-funded research. Additionally, PharmAla has appointed Ali Taghva as Chief Commercial Officer to enhance its commercial operations.
PharmAla Biotech Holdings Inc. has entered into an exclusive distribution agreement with Duchefa Farma B.V. to distribute its LaNeo MDMA in the Netherlands. This strategic partnership is expected to open new market opportunities for PharmAla, leveraging Duchefa’s strong presence and relationships in the European market. The agreement includes annual purchase minimums and provisions for increased demand following regulatory changes in the Netherlands, potentially enhancing PharmAla’s industry positioning and contributing to the acceptance of MDMA-Assisted Therapy for PTSD treatment.
PharmAla Biotech Holdings Inc. has successfully completed the shipment of its LaNeo™ MDMA to UCLA for a clinical trial investigating schizophrenia. This marks the first shipment of MDMA capsules across the American/Canadian border, highlighting the company’s role in addressing the unmet need for MDMA in the United States for clinical trial use. The trial, led by Dr. Bershad and Dr. Marder, faced challenges due to regulatory approvals, but PharmAla is committed to supporting the research, which could significantly contribute to the scientific understanding of MDMA.
PharmAla Biotech Holdings Inc. has announced the progression of its contract with the University of Texas Health Science Center at San Antonio, funded by the Defense Appropriations Act. This contract involves the development of a new 20mg clinical drug product dose of LaNeo™ MDMA, which will be used in a trial to treat PTSD in active-duty military personnel. The trial, part of the STRONG STAR Consortium, aims to explore MDMA-Assisted Therapy’s effects on this novel patient population. This collaboration highlights PharmAla’s commitment to supporting military psychological health research and could significantly impact treatment options for military personnel.
PharmAla Biotech Holdings Inc. has entered into an advisory agreement with shareholder Matthew Azrieli, who is expected to aid the company in its expanding U.S. clinical trials business and other growth markets. The agreement includes potential performance-based rewards for Azrieli, aimed at bolstering media, market, and investment advisory efforts. This strategic move is likely to enhance PharmAla’s market position and operational growth, particularly in the U.S., potentially benefiting its stakeholders.